T. Morris

First name
Last name
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799
Dashtban, A., Mizani, M. A., Denaxas, S., Nitsch, D., Quint, J., Corbett, R., et al. (2022). A retrospective cohort study measured predicting and validating the impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney Int. http://doi.org/10.1016/j.kint.2022.05.015
Whittaker, H., Rubino, A., Mullerova, H., Morris, T., Varghese, P., Xu, Y., et al. (2022). Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. Int J Chron Obstruct Pulmon Dis, 17, 427-437. http://doi.org/10.2147/copd.s346591
Martin-Merino, E., Johansson, S., Morris, T., & Rodriguez, L. A. G. (2011). Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care. Drug Saf. http://doi.org/10.2165/11594540-000000000-00000
Kerkhof, M., Chaudhry, I., Pavord, I. D., Miravitlles, M., Rhee, K., Halpin, D. M. G., et al. (2020). Blood eosinophil count predicts treatment failure and hospital readmission for COPD. ERJ Open Res. http://doi.org/10.1183/23120541.00188-2020